A controlled therapeutic trial in paucibacillary leprosy comparing a single dose of rifampicin with a single dose of rifampicin followed by one year of daily dapsone

SR Pattyn, G Groenen, L Janssens, L Kuykens, LB Mputu

Research output: Contribution to journalA1: Web of Science-article

Abstract

The cure rates of two treatment regimens in PB leprosy were compared in a prospective randomized trial: treatment U consisting of a single dose of rifampicin 40 mg/K bodyweight, and treatment A of rifampicin 1500 mg in a single dose, followed by one year of daily dapsone 100 mg. In patients with a BI = 0, the cure rates evaluated on the basis of histopathology of skin biopsies, were identical for the two regimens but in patients with a BI = 1, cure and relapse rates were unacceptable. For this reason and particularly the need to separate patients on the basis of the BI in skin biopsies, the single dose regimen does not appear to be suited for wide-scale application
Original languageEnglish
JournalLeprosy Review
Volume62
Pages (from-to)179-185
ISSN0305-7518
Publication statusPublished - 1991

Keywords

  • B780-tropical-medicine
  • Bacterial diseases
  • Leprosy
  • Treatment
  • Single dose
  • Rifampicin
  • Dapsone
  • Congo-Kinshasa
  • Africa-Central

Fingerprint Dive into the research topics of 'A controlled therapeutic trial in paucibacillary leprosy comparing a single dose of rifampicin with a single dose of rifampicin followed by one year of daily dapsone'. Together they form a unique fingerprint.

Cite this